TILAKNAGAR INDUSTRIES LTD.-$

Tilaknagar Industries Ltd announced that its Nomination and Remuneration Committee has approved the grant of 10,65,000 stock options to eligible employees under its Employees Stock Option Scheme 2025. The grant was made via a circular resolution on August 15, 2026. Each option, when exercised, will convert into one equity share of face value ₹10. The exercise price is set at ₹382 per stock option. The vesting period commences from the grant date, with a phased vesting schedule over five years. Options can be exercised within two years from the respective vesting period. Shares allotted upon exercise are not subject to a lock-in period.

Tilaknagar Industries Ltd announced that its Nomination and Remuneration Committee has approved the grant of 10,65,000 stock options to eligible employees under the Employees Stock Option Scheme 2025. The options are exercisable at ₹382 per option. Vesting will occur over five years, with 10% after the first year, 20% after the second, 30% after the third, and 40% after the fourth year. The exercise period is two years from the respective vesting date. The shares allotted upon exercise will not be subject to a lock-in period.

Tilaknagar Industries Limited (TI) announced its strongest-ever sales performance in Karnataka for July 2026, with its brand Imperial Blue also achieving record volumes. TI recorded 3 lakh cases in sales, a 30% year-on-year growth, and achieved 40% market share in the Prestige & Above segment. Imperial Blue sold over 1.5 lakh cases, a 50%+ growth, capturing 43% market share in the Deluxe Whisky segment. This milestone highlights TI's strong execution, expanded portfolio, and deep consumer connect in a key market, following its recent achievement of becoming the largest IMFL player in Telangana. The company sees significant growth opportunities in Karnataka, supported by the state's evolving excise policy encouraging premiumization.

Tilaknagar Industries Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its preferential issue of equity shares and convertible share warrants. The report, issued by CRISIL Ratings Limited, confirms no deviation from the stated objects of the issue. The preferential issue, which occurred between September 20-30, 2025, raised gross proceeds of ₹2295.63 crores, comprising ₹1,746.31 crores from convertible warrants and ₹549.32 crores from equity shares. The report has been reviewed by the company's Audit Committee and Board of Directors.

Tilaknagar Industries Ltd. announced its Q1 FY27 financial results, reporting a record net revenue of ₹1,046 crores, a 166% year-on-year increase. Volume grew by 172% YoY to 8.7 million cases. EBITDA saw a 79% YoY growth to ₹169 crores. Profit After Tax (PAT) increased by 9% to ₹96 crore. The company highlighted successful integration of Imperial Blue operations and reaffirmed its position as the largest domestic Prestige & Above IMFL player. They are preparing to accelerate expansion of their luxury and super-premium portfolio.

Tilaknagar Industries Ltd. announced the appointment of Ms. Bhumika Batra as an Additional Independent Director during its Board meeting held on July 27, 2026. Her tenure is for a period of 3 years, commencing from July 27, 2026, to July 26, 2029, subject to member approval within three months. Ms. Batra brings over 22 years of experience in corporate laws, mergers, acquisitions, and regulatory compliance. She is a partner at Crawford Bayley & Co. and has extensive experience in corporate governance and ESG.

Tilaknagar Industries Ltd. announced that its Board of Directors, in a meeting held on July 27, 2026, considered and approved the unaudited financial results for the quarter ended June 30, 2026. The results were consolidated and standalone, accompanied by limited review reports from statutory auditors M/s. Harshil Shah & Company. Additionally, the Board approved the appointment of Ms. Bhumika Batra as an Additional Independent Director for a three-year term, subject to member approval. Ms. Batra brings over 22 years of experience in corporate law and governance.

Tilaknagar Industries Ltd announced the appointment of Ms. Bhumika Batra as an Additional Independent Director to its Board of Directors. The decision was made during a Board Meeting held on July 27, 2026, following a recommendation from the Nomination and Remuneration Committee. Ms. Batra's appointment is for a term of three years, commencing July 27, 2026, and concluding on July 26, 2029, subject to shareholder approval within three months. She brings over 22 years of experience in corporate laws, mergers, acquisitions, and regulatory compliance, having served as a Partner at Crawford Bayley & Co. and holding an executive program in management from Cornell University. Ms. Batra is not related to any existing directors of the company and has a distinguished profile in corporate governance and ESG.

Tilaknagar Industries Ltd. announced the appointment of Ms. Bhumika Batra as an Additional Independent Director to its Board of Directors. The decision, made based on the recommendation of the Nomination and Remuneration Committee, was approved at a board meeting held on July 27, 2026. Ms. Batra's appointment is for a term of 3 years, commencing July 27, 2026, and concluding on July 26, 2029, subject to shareholder approval within three months. She brings over 22 years of experience in corporate laws, including M&A, private equity, and regulatory compliance. The board meeting also considered and approved the Unaudited Financial Results for the quarter ended June 30, 2026.

Tilaknagar Industries' first full quarter with the acquired Imperial Blue (IB) business transformed its scale but not yet its profit. Consolidated revenue from operations rose ~165% YoY to ₹2,252 Cr (net of ₹1,206 Cr excise duty, ~₹1,046 Cr), driven entirely by the IB division bought from Pernod Ricard for ₹3,442 Cr (completed Dec 2025). Consolidated PAT, however, fell to ₹31.6 Cr from ₹88.5 Cr a year ago — down ~64% reported, and still down ~30% even after excluding the ₹30.1 Cr exceptional charge for IB integration and transition costs. So the revenue explosion is inorganic and the bottom line went backwards on a like-for-like basis. The margin bridge explains the gap. Operating EBITDA of ~₹173 Cr translates to roughly 16% of net revenue — landing at the lower end of the 16–18% band management/brokerages have guided for FY27, consistent with the "margins near the low end" framing given near-term raw-material inflation. Below EBITDA, two acquisition-driven lines crush the print: finance costs jumped to ₹66.4 Cr (from ₹2.8 Cr a year ago) on the debt funding the deal, and depreciation rose to ₹45.5 Cr (from ₹7.3 Cr). Tax expense was nil. The result is a profit that is thin relative to the enlarged asset and debt base — the classic shape of an integration year. Sequentially the quarter reads better: revenue grew ~8% QoQ and the company swung back to a ₹31.6 Cr profit from a ₹14.9 Cr consolidated loss in Q4 FY26, when exceptional costs peaked. Operationally momentum is real — June 2026 saw a record 3.4 million cases and IB crossed 2 million cases in both May and June — which supports management's high-single to low-double-digit FY27 volume guide. Concurrent board actions this quarter fit the integration theme: approval of a composite amalgamation of two wholly-owned subsidiaries (Punjabexpo Breweries, Vahni Distilleries; appointed date 1 Apr 2026, pending NCLT), incorporation of a Nigeria WOS, and the addition of an independent director. No published Q1 street consensus was found, so the print is best judged against guidance rather than a number: margins met the low end, volumes are tracking, but reported profitability remains suppressed until integration costs roll off and the ₹3,442 Cr acquisition debt is worked down (management targets net debt/EBITDA below 1.0x by FY29). The auditor's qualified conclusion on the un-assessed ENA-plant impairment is an outstanding governance flag, not a P&L event this quarter.